Preview: India's Cipla slips ahead of quarterly results on concerns over weak US sales

Cipla

13/05/2026 05:36

** Shares of Cipla CIPL.NS fall 0.57% to 1,284.90 rupees ahead of Q4 results; Nifty Pharma .NIPHARM index down 0.16%

** Analysts, on average, expect 42% YoY profit drop, revenue to rise marginally - LSEG-compiled data

** Jefferies flags near-term U.S. sales decline due to key product erosion, margin pressure until new launches scale

** Nomura notes market share loss in hormone therapy drug Lanreotide, supply constraints to impact sales

** CIPL rival Dr Reddy's REDY.NS reported 86% profit drop Tuesday on weaker cancer drug demand, U.S. competition

 ** CIPL rated "hold" on average by 37 analysts, median PT 1,438 rupees - LSEG-compiled data

** YTD, CIPL down 14.5%, REDY dropped 0.11%, Nifty Pharma up 5.1%

($1 = 95.6300 Indian rupees)

(Reporting by Surbhi Misra in Bengaluru)

((Surbhi.Misra@thomsonreuters.com |  X: https://twitter.com/SurbhiMisra_  |;))